GLP-1 advertising rules tightened fast in 2026, and a lot of med spas and wellness clinics found out the hard way — mid-campaign, with a Google or Meta account suddenly disabled. If your practice offers semaglutide, tirzepatide, or any compounded weight-loss program, the ad rules you were following a year ago are no longer enough. The FDA sent two separate waves of warning letters to telehealth and compounding companies in 2026, Meta rewrote its policy on before-and-after weight-loss imagery, and both Google and Meta are now leaning harder on LegitScript certification before they’ll approve a campaign at all.
None of this means you can’t advertise GLP-1 or weight-loss services. It means the margin for error is smaller, and the penalty for getting it wrong — a suspended ad account, not just a rejected ad — is a lot more expensive than it used to be. Here’s what actually changed, in plain terms, and what to check before your next campaign goes live.
Why GLP-1 Ads Are Getting Rejected and Accounts Suspended
Three things are colliding at once. First, patient demand for GLP-1 treatments through med spas and wellness clinics kept climbing through 2026, which means more practices are advertising them for the first time — often without realizing weight-loss and prescription-adjacent content sits in a more heavily restricted ad category than general aesthetics. Second, the FDA has been actively enforcing against telehealth and compounding companies over how these products are marketed online, not just how they’re dispensed. Third, Google and Meta have both been tightening enforcement on health-adjacent verticals generally, and GLP-1 content is caught directly in that sweep because it touches prescription medication, weight loss claims, and personal health attributes all at once.
The result is that an ad which would have run without issue in 2024 can now trigger an automatic disapproval, or in worse cases, a full account suspension, even if nothing about the offer itself changed.
What the FDA Is Actually Enforcing Right Now
On March 3, 2026, the FDA sent warning letters to 30 telehealth companies over misleading marketing of compounded GLP-1 products, following more than 40 similar letters sent in late 2025. A second wave went out to another 25 companies on June 16, 2026. Both waves targeted the same core problems:
- Marketing language implying a compounded product is “equivalent to” or as effective and safe as an FDA-approved semaglutide or tirzepatide drug
- Safety or effectiveness claims with no substantiation behind them
- Listing the practice or telehealth platform as the “manufacturer” when it isn’t actually the compounding entity
- Describing a compounding pharmacy or facility as “FDA-approved” or “FDA-licensed” — a designation the FDA does not issue to compounders
Companies that received letters were given 15 business days to submit a corrective action plan. The FDA’s own language on this is worth repeating for anyone running a compounded GLP-1 program: compounding serves a legitimate purpose for patients who need it, but a compounder mass-marketing a copy of an approved drug as if it went through the same approval process is a misbranding problem, not just a marketing one.
Practically, this means every claim on your landing page and in your ad copy needs to be checked against what your specific product actually is. “Medical weight loss” and “GLP-1 treatment” are fine as category descriptions. “Same as Ozempic” or “FDA-approved” language attached to a compounded product is exactly what’s drawing enforcement action.
Meta’s Rules for GLP-1 and Weight-Loss Ads
Meta treats weight-loss, cosmetic, and supplement ads as restricted health content, and its 2026 policy has a few specific requirements that trip up practices most often:
- Age targeting: 18+ targeting is mandatory on all weight-loss, cosmetic, and supplement ads. There’s no exception for a broader wellness campaign that happens to mention GLP-1s.
- No personal attributes: Meta prohibits ad copy that implies something about the viewer’s body or health directly. “Tired all the time?” passes; “Hate your belly?” or “Struggling with your weight?” violates policy because it asserts a personal attribute about the person seeing the ad.
- Before-and-after imagery: As of July 22, 2026, Meta allows before-and-after photos for cosmetic procedures again, but only with written patient authorization on file and no language implying guaranteed results.
- Prescription products need written permission: Ads promoting a prescription weight-loss product require Meta’s written approval before the campaign can run at all — this is a manual review step, not an automatic policy check.
We covered the broader shift in healthcare ad enforcement on Meta, including how it now treats lead-gen forms and tracking pixels for physician and dental practices, in Meta Ads Restrictions for Practices: What Changed in 2026 — the same account-level scrutiny applies to med spas running GLP-1 campaigns.
Google Ads and the LegitScript Requirement
Google’s restriction runs through a third-party credential: LegitScript healthcare merchant certification. If your GLP-1 program involves a pharmacy, compounding partner, or telemedicine component that ends in a prescription, Google will generally require LegitScript certification before it approves the campaign — and Meta is leaning the same direction for the same category of offer.
LegitScript certification isn’t free or instant. Budget roughly $975 for the initial application per website, plus around $2,150 a year to maintain it. The review looks at your website’s claims, your clinical and prescribing infrastructure, and whether your documented processes actually match what you’re advertising. It typically takes several weeks, so it needs to happen before a campaign launch is planned, not after an ad gets rejected.
Meta vs. Google vs. FDA: Quick Reference
| Requirement | Meta | Google Ads | FDA |
|---|---|---|---|
| Third-party certification | Required for many prescription-adjacent offers | LegitScript certification generally required | Not applicable (not an ad platform) |
| Age/audience targeting | 18+ mandatory, no exceptions | Follows healthcare & medicines policy | N/A |
| Before/after imagery | Allowed since July 22, 2026, with written consent, no guaranteed-result language | Reviewed case-by-case under health content policy | Regulates on-site/landing page claims, not ad creative directly |
| “Equivalent to” claims | Can trigger manual review or rejection | Can trigger disapproval | Direct enforcement target (2026 warning letters) |
| Consequence of violation | Ad disapproval → account warning → suspension | Ad disapproval → account suspension → domain flag | Warning letter → 15 business days to correct → further action |
Compounded Semaglutide vs. Brand-Name GLP-1s: Why the Ad Rules Differ
The rules above land differently depending on what your practice is actually dispensing. Brand-name, FDA-approved GLP-1 medications carry standard prescription-drug advertising restrictions, but they don’t carry the added scrutiny that compounded versions currently do. Compounded semaglutide and tirzepatide exist in a narrower legal lane — compounding is legitimate when a patient has a documented clinical need that an approved product can’t meet, but it isn’t meant to be marketed as an interchangeable, mass-market alternative to the approved drug. That distinction is exactly what the FDA’s 2026 warning letters were about, and it’s why ad copy that blurs the line between “compounded” and “the same as” is the highest-risk category right now.
If your practice offers both options, keep the ad copy, landing pages, and disclosures clearly separated by product rather than writing one generic “GLP-1 weight loss” campaign that covers both.
A Pre-Launch Compliance Checklist
Before a GLP-1 or weight-loss campaign goes live on Meta or Google, it’s worth running through this list:
- Confirm whether your offer requires LegitScript certification, and if so, that it’s active — not just submitted
- Remove any language suggesting a compounded product is “equivalent to,” “same as,” or “as effective as” an FDA-approved drug
- Check ad copy for personal-attribute language (“your weight,” “your body”) and rewrite toward the condition or service instead
- Confirm 18+ age targeting is set on every ad set touching weight loss or prescription content
- If using before-and-after images, confirm written patient authorization is on file and that no copy implies guaranteed results
- Make sure your landing page claims match your ad claims exactly — a compliant ad linking to a non-compliant page still gets flagged
- Have someone outside the campaign read the ad copy and landing page specifically looking for FDA-approval or manufacturer-status claims that aren’t accurate
This is also where marketing tracking overlaps with compliance in a way a lot of practices miss: if your GLP-1 landing pages capture any patient health information through forms, chat widgets, or pixels, that data is subject to the same handling rules covered in HIPAA Compliant Marketing Tracking: What Practices Need in 2026 — a compliant ad account doesn’t help if the intake form behind it isn’t compliant too.
What Happens If You Get It Wrong
The escalation path is consistent across platforms, and it’s steeper than most practices expect. A single non-compliant ad usually just gets disapproved. Repeated violations move the account into a warning state. Past that point, both Google and Meta can suspend the entire ad account — not just the offending campaign, all of it, including unrelated campaigns running for other services at the same practice. Reinstatement isn’t guaranteed, and when it happens, it can take weeks or months. In more serious cases, the domain itself gets flagged, which can block new ad accounts from being opened on that same website going forward.
That’s the real cost of treating GLP-1 advertising like any other campaign: a policy miss doesn’t just cost one ad, it can cost the whole account, and a suspended dental or general-practice account is exactly as disruptive whether the trigger was the weight-loss line of business or not.
FAQ: GLP-1 Advertising Rules for Med Spas
Do I need LegitScript certification to advertise GLP-1 treatments?
If your program involves a pharmacy, compounding partner, or telehealth prescribing component, Google generally requires LegitScript healthcare merchant certification before approving the campaign, and Meta increasingly expects the same for prescription-adjacent offers.
Can I use before-and-after weight-loss photos in my ads?
On Meta, yes, as of July 22, 2026, but only with written patient authorization on file and no language implying guaranteed results. Google reviews before-and-after imagery case by case under its health content policy.
Why did my Google or Meta ad account get suspended over a GLP-1 ad?
Usually because of repeated policy violations rather than a single ad — missing certification, prohibited personal-attribute language, or claims implying FDA approval for a compounded product. Suspensions typically follow a pattern of disapprovals, not a first offense.
Is it legal to advertise compounded semaglutide?
It can be, but the FDA’s 2026 enforcement specifically targets marketing that implies a compounded product is equivalent to or as safe and effective as an FDA-approved GLP-1 drug. Advertising the service itself is different from making equivalence claims about the medication.
Do these rules apply the same way to Instagram and TikTok ads?
Instagram ads run under Meta’s ad policies, so the same rules apply directly. TikTok has its own separate health advertising policy, which practices should check independently rather than assuming Meta’s rules carry over.
What’s the difference between advertising a brand-name GLP-1 and a compounded version?
Brand-name, FDA-approved GLP-1s follow standard prescription-drug advertising rules. Compounded versions carry extra scrutiny in 2026 because compounding is meant for documented clinical need, not as a mass-marketed substitute for the approved drug — and blurring that line is what’s drawing FDA warning letters.
GLP-1 demand isn’t slowing down, and neither is enforcement around how it gets advertised. The practices avoiding disruption this year aren’t the ones with the most aggressive campaigns — they’re the ones checking certification status, ad copy, and landing pages against the current rules before launch, not after a disapproval notice shows up.
